List of Excipients in Branded Drug APRISO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	ANHYDROUS CITRIC ACID
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	ASPARTAME
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	CELLULOSE, MICROCRYSTALLINE
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	CROSPOVIDONE
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	HYPROMELLOSE
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	MAGNESIUM STEARATE
Aphena Pharma Solutions - Tennessee LLC	APRISO	mesalamine	43353-884	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

APRISO Excipient Strategy and Commercial Opportunities in Mesalamine Extended-Release Capsules

Last updated: August 26, 2026

APRISO is a 0.375 g mesalamine extended-release capsule approved for maintenance of remission in adults with ulcerative colitis. Its commercial value depends on multiparticulate delivery, delayed release in the gastrointestinal tract, capsule manufacturability, and reliable control of dissolution performance. The strongest excipient opportunities are in enteric coating systems, sustained-release matrices, functional fillers, process aids, and supplier-backed formulation equivalence for generic or authorized-generic products.

What is APRISO and how does its formulation work?

APRISO contains mesalamine, also known as 5-aminosalicylic acid or 5-ASA. The labeled dose is four 0.375 g capsules taken once daily, for a total daily dose of 1.5 g [1].

APRISO uses a multiparticulate oral delivery system. The capsule contains coated mesalamine units designed to release the active ingredient in the colon rather than immediately in the stomach or proximal small intestine. This approach is commercially important because mesalamine has local anti-inflammatory activity in the colonic mucosa, and formulation performance directly affects site-specific exposure.

Product attribute	APRISO specification
Active ingredient	Mesalamine
Strength	0.375 g per capsule
Labeled dose	1.5 g once daily
Dosage form	Extended-release capsule
Therapeutic area	Ulcerative colitis
FDA pathway	New drug application
NDA	NDA 022372
Target release site	Colon
Product type	Small-molecule oral drug
Biosimilar relevance	None; generic drug pathways apply

The product is not a biologic, so biosimilar competition is not relevant. Competitive entry generally proceeds through an abbreviated new drug application, subject to pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

What excipients are used in APRISO?

The FDA prescribing information identifies several inactive ingredients used in the capsule and its multiparticulate dosage units. The listed excipient set includes colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, talc, titanium dioxide, and FD&C Yellow No. 6 [1].

The formulation also depends on functional coating materials and capsule components. For commercial development, the most important excipient categories are:

Excipient category	Likely functional role	Commercial relevance
Microcrystalline cellulose	Core diluent and structural carrier	Controls granule strength, density, and powder flow
Povidone	Binder	Supports drug-layer adhesion and granule integrity
Sodium starch glycolate	Disintegrant	Promotes post-release breakup of dosage units
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves flow and may reduce manufacturing variability
Magnesium stearate	Lubricant	Controls ejection and reduces tooling adhesion
Talc	Anti-tacking and coating aid	Supports coating uniformity and processing
Titanium dioxide	Opacifier and colorant	Controls capsule or coating appearance
FD&C Yellow No. 6	Colorant	Supports product identification
Enteric polymer system	Delayed-release barrier	Controls gastric resistance and intestinal or colonic release
Capsule shell	Dosage-unit enclosure	Determines filling, appearance, and packaging performance

The enteric coating system is the most strategically important portion of the excipient architecture. Exact qualitative and quantitative composition, coating weight gain, polymer grade, pore structure, and manufacturing sequence may be protected as confidential know-how even where the public label identifies inactive ingredients.

What formulation attributes make APRISO difficult to copy?

Generic developers must reproduce more than the active ingredient and capsule strength. They must match the release profile of a multiparticulate system across relevant dissolution conditions.

Key technical variables include:

1. Drug loading and particle-size distribution.
2. Core density and granule friability.
3. Binder concentration and wetting conditions.
4. Coating polymer type and ratio.
5. Coating weight gain and thickness distribution.
6. Plasticizer level and film flexibility.
7. Talc or anti-tacking concentration.
8. Residual solvent and moisture content.
9. Capsule fill weight and unit-to-unit distribution.
10. Dissolution performance across acidic, intestinal, and higher-pH media.

Mesalamine is particularly sensitive to formulation design because premature release can increase upper-gastrointestinal exposure while reducing delivery to the colon. Excessive coating strength can create the opposite problem: delayed or incomplete release and reduced local availability.

The principal development risk is failure to replicate the reference product's in vitro release behavior. A formulation may meet assay and content-uniformity specifications yet fail comparative dissolution or bioequivalence requirements.

What excipient strategy is most attractive for APRISO generics?

The most defensible strategy is to use compendial, widely qualified excipients while differentiating the performance-critical coating system and process controls.

Enteric coating strategy

A developer can evaluate methacrylic acid copolymers, cellulose-based enteric polymers, or combinations of pH-sensitive polymers. The selection should be driven by:

• Gastric resistance.
• Release onset at target pH.
• Film integrity during storage.
• Compatibility with mesalamine.
• Low coating defects.
• Availability from more than one supplier.
• Regulatory precedent in oral delayed-release products.

Polymer grade is as important as polymer identity. Molecular weight, particle size, neutralization level, dispersion properties, and residual monomer profile can alter release performance.

Core and binder strategy

Microcrystalline cellulose and povidone are commercially attractive because they have broad regulatory use and multiple qualified suppliers. Substitution still requires comparative evaluation. Changes in cellulose grade can alter porosity, granule density, liquid uptake, and coating adhesion.

A developer seeking a robust supply chain should qualify at least two sources for critical excipients where the pharmacopoeial monograph does not fully control functional performance.

Lubricant strategy

Magnesium stearate is widely available but can affect wettability and dissolution if over-lubrication occurs. Mixing time, lubricant surface area, and shear exposure should be controlled as critical process parameters. Alternative lubricants may offer process advantages but increase comparability and regulatory risk.

Color and capsule-shell strategy

Colorants and titanium dioxide create lower technical differentiation but can affect product identification, regional acceptability, and supply continuity. A color-free or reformulated capsule may be commercially viable, but any change must preserve appearance, stability, packaging compatibility, and approved labeling requirements.

What commercial opportunities exist in APRISO excipients?

Generic and authorized-generic supply

APRISO's once-daily dosing and established use in ulcerative colitis create a continuing market for generic extended-release mesalamine. Excipient suppliers can participate through:

• Direct supply of enteric polymers.
• Contract coating services.
• Formulation-development partnerships.
• Comparative dissolution support.
• Dual-source excipient qualification.
• Regulatory documentation packages.
• Stability and extractables support.

The highest-value opportunity is usually the coating system rather than commodity excipients such as talc or magnesium stearate.

Reformulated mesalamine products

A manufacturer could use the APRISO formulation concept to develop products with:

• Lower capsule burden.
• Alternative capsule sizes.
• Improved swallowability.
• Modified color or shell composition.
• Reduced exposure to specific excipients.
• Enhanced moisture protection.
• Regional versions using locally accepted excipient systems.

A lower capsule burden is commercially relevant because the reference regimen requires four capsules daily. Any reformulation must establish comparable release and clinical performance.

Excipient substitution programs

Drug shortages, supplier consolidation, and regional regulatory restrictions create demand for qualified substitutions. Potential substitution projects include:

• Alternate grades of microcrystalline cellulose.
• Alternate povidone molecular weights.
• Different colloidal silicon dioxide suppliers.
• Substitute enteric polymers.
• Alternative capsule-shell vendors.
• Replacement color systems.

The commercial barrier is not excipient availability. It is demonstrating that the substitution does not alter dissolution, stability, or bioequivalence.

Manufacturing technology

Continuous or automated coating systems may reduce batch variability and improve coating-weight control. Process analytical technology can monitor:

• Spray rate.
• Inlet and outlet temperature.
• Bed temperature.
• Atomization pressure.
• Coating weight gain.
• Moisture endpoint.
• Agglomeration.
• Tablet or granule defects.

Equipment vendors and contract manufacturers can commercialize APRISO-compatible platforms by demonstrating control of delayed-release multiparticulates rather than merely supplying standard capsule-filling capacity.

What patents protect APRISO and its formulation?

APRISO's commercial protection has historically depended on the approved drug product, regulatory exclusivity, formulation know-how, and any applicable patent rights. The FDA Orange Book is the primary source for patents and exclusivity associated with an approved small-molecule drug product [2].

APRISO's original regulatory exclusivity has expired. Patent protection for a product launched in the 2000s would also generally be expected to have reached or approached expiry unless patent-term adjustment, patent-term extension, or later-issued formulation patents applied.

The commercially relevant IP categories are:

IP category	Relevance to APRISO competition
Composition-of-matter patent	Low current relevance because mesalamine is an established active ingredient
Multiparticulate formulation patent	Could cover coating architecture, release profile, or pellet structure
Method-of-use patent	Could cover dosing or treatment of ulcerative colitis
Manufacturing patent	Could cover coating, granulation, or process conditions
Trade secret	May protect coating parameters, scale-up methods, and specifications
Regulatory exclusivity	Original exclusivity period has expired
Orange Book listing	Must be checked for current patent entries and delisting status

A competitor should conduct a current Orange Book review, USPTO patent search, and litigation search before relying on any conclusion about freedom to operate. Patent expiry is not the only issue. A formulation patent may be expired while confidential process know-how still creates a practical manufacturing barrier.

When did APRISO lose exclusivity?

APRISO received FDA approval in 2008. Its five-year new-chemical-entity exclusivity period therefore ended in 2013, subject to the exact approval date and any regulatory adjustments [1, 3].

Because mesalamine was already known and approved before APRISO, the product's commercial protection did not arise from a new chemical entity. Generic competition has therefore been possible through the ANDA pathway once applicable patent and exclusivity barriers expired.

Milestone	Timing
FDA approval of APRISO	2008
Five-year NCE exclusivity	Ended approximately 2013
Generic pathway	ANDA, subject to applicable patent certifications
Current competitive issue	Product-specific bioequivalence and release performance

What Paragraph IV challenges and litigation affect APRISO?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. For APRISO, the importance of Paragraph IV litigation depends on whether any active Orange Book-listed patents remain associated with NDA 022372.

No current litigation conclusion should be inferred solely from the existence of historical generic approvals. Litigation status can change through patent expiration, settlement, dismissal, or later enforcement activity. The key documents are:

• FDA Orange Book patent listings.
• ANDA notice letters.
• District court complaints.
• Federal Circuit decisions.
• Settlement agreements.
• FDA approval letters.
• Generic product labeling.

A generic developer's strongest position generally comes from an early patent review combined with a non-infringement formulation design. A coating system that achieves comparable release through materially different polymer ratios or process conditions may reduce infringement exposure, although it does not eliminate regulatory comparability requirements.

What is the FDA and Orange Book status of APRISO?

APRISO is an FDA-approved prescription drug marketed as mesalamine extended-release capsules. The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patents, and exclusivity information where applicable [2].

The commercial status is consistent with a mature small-molecule product:

• FDA approval is established.
• NCE exclusivity is expired.
• Generic substitution is possible where an approved generic receives an AB rating.
• Biosimilar regulation does not apply.
• Product-specific dissolution and bioequivalence remain central.
• Patent and litigation status require current database verification.

How strong is the APRISO patent estate?

The current patent estate should be viewed as weaker than the formulation and manufacturing barriers. Mesalamine is a long-established active ingredient, and the principal differentiation lies in the release platform and product execution.

Protection layer	Relative strength
Active ingredient	Low
Basic oral capsule concept	Low
Delayed-release multiparticulates	Moderate, depending on claims and expiry
Exact coating process	Moderate to strong as know-how
Manufacturing specifications	Strong operational barrier
Regulatory approval	Mature and accessible through ANDA
Brand loyalty and prescribing history	Moderate commercial barrier
Supply-chain reliability	Potential competitive differentiator

The most durable advantage is likely to come from manufacturing consistency, validated release performance, supply reliability, and payer access rather than from broad active-ingredient patents.

What generic launch risks exist for APRISO?

Generic launch risks fall into four categories:

1. Bioequivalence risk. The applicant may fail to match the reference product's release behavior.
2. CMC risk. Coating defects, granule variability, or moisture changes can destabilize performance.
3. Patent risk. An overlooked formulation or method-of-use patent can delay launch or trigger litigation.
4. Commercial risk. Multiple mesalamine products compete across delayed-release tablets, capsules, enemas, and suppositories.

A successful launch requires a formulation that is technically equivalent but commercially manufacturable. The preferred excipient strategy minimizes dependence on a single supplier, avoids unnecessary novel excipients, and preserves flexibility in coating operations.

How does APRISO compare with other mesalamine products?

APRISO competes with other oral mesalamine formulations, including delayed-release tablets, extended-release capsules, and higher-dose products. These products are not automatically interchangeable because release mechanisms, dosing schedules, strengths, and approved indications can differ.

Product type	Typical differentiation
APRISO	Once-daily extended-release capsule; multiparticulate delivery
Delayed-release mesalamine tablet	Enteric protection; often different dosing schedule
High-strength mesalamine tablet	Lower unit count at higher dose
Rectal mesalamine	Local delivery to distal colon and rectum
Combination oral and rectal therapy	Broader colonic coverage in selected patients

The opportunity for excipient suppliers is strongest where a product requires site-specific release and low batch-to-batch variability. Standard immediate-release mesalamine has fewer formulation barriers.

Key Takeaways

• APRISO is a 0.375 g mesalamine extended-release capsule approved for ulcerative-colitis maintenance therapy.
• Its value is concentrated in multiparticulate delivery and delayed release, not in the mesalamine molecule.
• The principal excipient opportunity is the enteric coating system, followed by binders, functional fillers, lubricants, and capsule components.
• APRISO's five-year NCE exclusivity ended approximately in 2013.
• Generic competition proceeds through the ANDA pathway, with dissolution and bioequivalence as major technical hurdles.
• Biosimilar risk does not apply because APRISO is a small-molecule drug.
• Manufacturing know-how, coating control, supplier qualification, and stability data may provide more durable protection than expired or narrow patents.
• Commercial opportunities include generic supply, excipient substitution, contract coating, reformulation, and process-analytical technology.
• Current Orange Book listings and litigation records should control any launch or freedom-to-operate decision.

FAQs About APRISO Excipient Strategy

What is the most important excipient in APRISO?

The most important excipient category is the enteric coating system because it determines gastric resistance and release-site performance. Polymer grade, coating thickness, plasticizer content, and process conditions all affect dissolution.

Can a generic APRISO product use different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the formulation meets applicable FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, stability, safety, and comparable release performance.

Is APRISO protected by biologic exclusivity?

No. APRISO contains mesalamine, a small molecule. Generic applicants use the ANDA pathway rather than the biosimilar pathway.

Does changing the capsule color create a new APRISO patent opportunity?

Usually not. A capsule-color change may support product differentiation or address supply constraints, but color alone generally provides limited patent value. Commercial value would depend on a broader formulation, manufacturing, or device innovation.

What is the largest commercial barrier to a generic APRISO launch?

The largest barrier is usually reproducible release performance from the multiparticulate coating system. A generic product must control coating uniformity, dissolution, stability, and batch-scale manufacturing while meeting FDA requirements.

References

1. U.S. Food and Drug Administration. (2024). Apriso (mesalamine) extended-release capsules: Prescribing information. Salix Pharmaceuticals.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Approved drug product database and exclusivity information. https://www.fda.gov/drugs/drug-approvals-and-databases.